晚期胃及食管胃结合部腺癌患者循环肿瘤细胞的动态评估:预后价值与早期疗效评估
该研究纳入106例未经治疗的晚期胃及食管胃结合部腺癌(GOA)患者,在PRODIGE 17-ACCORD 20试验的辅助研究中,于第0天(D0)和第28天(D28)用CellSearch系统检测循环肿瘤细胞(CTC)。D0时CTC≥2为最佳阈值,D28时CTC≥2可预测疾病控制;结合D0和D28的CTC计数分为3组,无进展生存期(PFS)和总生存期(OS)差异显著。
要点
- D0时CTC≥2为最佳阈值,与更差OS和PFS显著相关。
- D28时CTC≥2可预测疾病控制。
- 结合D0和D28的CTC计数分组,PFS(p=0.0002)和OS(p=0.003)差异显著。
核心结论
- 基线和治疗期间CTC定量可能是晚期GOA有用的预后工具,与更差PFS和OS相关。
- CTC阈值≥2似乎具有最佳判别价值。
- 基线与D28之间CTC计数的变化可能有助于为每位患者个体化调整治疗。
研究设计与样本
- PRODIGE 17-ACCORD 20试验的辅助研究,纳入106例未经治疗的晚期GOA患者。
- 使用CellSearch系统在第0天(D0)和第28天(D28)检测外周血CTC。
- 通过测试多个阈值分析D0和D28时CTC的预后价值。
主要发现
- 基线时中位CTC计数为1(范围,0-415)。
- D0时CTC≥1、≥2或≥3均与更差OS和PFS显著相关,CTC≥2为D0或D28的最佳阈值。
- D28时CTC≥2也可预测疾病控制。
- 结合D0和D28的CTC计数定义3组(低/低、高/低和低-高/高),PFS(p=0.0002)和OS(p=0.003)差异显著。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The identification of dynamic biomarkers in advanced gastric and oesogastric junction adenocarcinoma (GOA) could help to tailor strategies for each patient. Enumeration of circulating tumour cells (CTCs) is approved by the US Food and Drug Administration in breast, colon and prostate cancer but is not in advanced GOA. Our study aims to establish the optimal threshold and the clinical significance of CTC count in advanced GOA before and during treatment. METHODS: One hundred six patients with untreated advanced GOA were included in the ancillary study of the PRODIGE 17-ACCORD 20 trial. CTCs were detected in the peripheral blood using the CellSearch system on day 0 (D0) and day 28 (D28). The prognostic value of CTCs at D0 and D28 was analysed by testing several thresholds. RESULTS: At baseline, median CTC count was 1 (range, 0-415). While CTCs ≥1, 2 or 3 at D0 were all significantly associated with worse overall survival (OS) and progression-free survival (PFS), CTCs ≥2 were the optimal threshold, on D0 or D28. CTCs ≥2 at D28 were also predictive of disease control. Taking into account both D0 and D28 CTC count defined 3 groups (low/low, high/low and low-high/high) with significantly different PFS (p = 0.0002) and OS (p = 0.003). CONCLUSION: Quantification of CTCs at baseline and during treatment may be a useful prognostic tool in advanced GOA, as it is associated with worse PFS and OS. A threshold ≥2 CTCs seems to have the best discriminant value. Change in CTC count between baseline and D28 could help to tailor treatment to each individual patient.
引用
- Pernot S, Badoual C, Terme M, et al. Dynamic evaluation of circulating tumour cells in patients with advanced gastric and oesogastric junction adenocarcinoma: Prognostic value and early assessment of therapeutic effects. Eur J Cancer. 2017. PMID: 28456090. doi:10.1016/j.ejca.2017.03.036
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。